Development of novel strategies for the chemoresistant pancreatic tumors using the patient-derived library

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K09454
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: The University of Tokyo
• Principal Investigator: TAKAHARA NAMINATSU 東京大学, 医学部附属病院, 助教 (10750622)
• Co-Investigator(Kenkyū-buntansha): 立石 敬介 東京大学, 医学部附属病院, 講師 (20396948)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: 膵癌

Outline of Final Research Achievements

In this project, we established the library of patient-derived tumor xenografts (PDX) and Patient-derived organoids (PDO). Using the system, we performed the drug screening in epigenetic field for the pancreatic cancer cells. Especially, we tried to analyze the mechanism of drug resistance in pancreatic cancer cells. We found the effectiveness of BET inhibitor against the growth of pancreatic cancer PDOs and published the report. We are conducting in vivo validation of in vitro data. Additionally, we analyze the function of target genes in pancreatic cancer.

Free Research Field

消化器病学

Academic Significance and Societal Importance of the Research Achievements

申請者らはこれまでに標準治療に抵抗性となった膵癌に対する腹腔内化学療法や新規化学療法regimen の開発に携わるとともに、遺伝子多型SNPや腫瘍マーカーを用いた治療効果予測の有用性を報告してきた。本研究では、患者由来ヒト膵癌異種移植腫瘍を用いることで、化学療法への耐性を改善する低分子化合物の探索とその機序の解明を試みた。ヒト膵癌細胞とマウスでの分子機序における相違点の有無についても解析を行い、新たな膵癌増殖抑制効果を持つエピゲノム分子としての意義を確立した。